Histone Deacetylase Inhibitors

Epigenetic Targets in Drug Discovery

Volumn 42, Issue , 2010, Pages 185-223

  Jones, Philip ^a  

^a IRBM   (Italy)

Author keywords

Epigenetics; Histone deacetylase; Inhibitors

Indexed keywords

EID: 85018193935     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527627073.ch9     Document Type: Chapter

References (104)

1. Yoo, C.B. and Jones, P.A. (2006) Epigenetic therapy of cancer: past, present and future. Nature Reviews Drug Discovery, 5, 37-50.
2. Taunton, J., Hassig, C.A. and Schreiber, S.L. (1996) A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p. Science, 272, 408-411.
3. Grant, S., Easley, C. and Kirkpatrick, P. (2007) Vorinostat. Nature Reviews Drug Discovery, 6, 21-22.
4. Bolden, J.E., Peart, M.J. and Johnstone, R.W. (2006) Anticancer activities ofhistone deacetylase inhibitors. Nature Reviews Drug Discovery, 5, 769-784.
5. Minucci, S. and Pelicci, P.G. (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Reviews Cancer, 6, 38-51.
6. de Ruijter, A.J.M., van Gennip, A.H., Caron, H.N., Kemp, S. and van Kuilenburg, A.B.P. (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochemical Journal, 370, 737-749.
7. Xu, W.S., Parmigiani, R.B. and Marks, P.A. (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene, 26, 5541-5552.
8. Abel, T. and Zukin, R.S. (2008) Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Current Opinion in Pharmacology, 8, 57-64.
9. Finnin, M.S., Donigian, J.R., Cohen, A., Richon, V.M., Rifkind, R.A., Marks, P.A. et al. (1999) Structures of a HDAC homologue bound to the TSA and SAHA inhibitors. Nature, 401, 188-193.
10. Vannini, A., Volpari, C., Filocamo, G., Casavola, E.C., Brunetti, M., Renzoni, D. et al. (2004) Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 101, 15064-15069;
11. Vannini, A., Volpari, C., Gallinari, P., Jones, P., Mattu, M., Carfi, A. et al. (2007) Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO Reports, 8, 879-884.
12. Somoza, J.R., Skene, R.J., Katz, B.A., Mol, C., Ho, J.D., Jennings, A.J. et al. (2004) Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (London, England: 1993), 12, 1325-1334.
13. Jones, P., Bottomley, M.J., Carfí, A., Cecchetti, O., Ferrigno, F., Lo Surdo, P. et al. (2008) 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 18, 3456-3461.
14. Leder, A. and Leder, P. (1975) Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells. Cell, 5, 319-322.
15. Riggs, M.G., Whittaker, R.G., Neumann, J.R. and Ingram, V.M. (1977) Butyrate causes histone modification in HeLa and Friend erythroleukemia cells. Nature, 268, 462-464.
16. Rephaeli, A., Zhuk, R. and Nudelman, A. (2000) Prodrugs ofbutyric acid from bench to bedside: synthetic design, mechanisms of action, and clinical applications. Drug Development Research, 50, 379-391.
17. Phiel, C.J., Zhang, F., Huang, E.Y., Guenther, M.G., Lazar, M.A. and Klein, P.S. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. The Journal of Biological Chemistry, 276, 36734-36741.
18. Miller, T.A., Witter, D.J. and Belvedere, S. (2003) Histone deacetylase inhibitors. Journal of Medicinal Chemistry, 46, 5097-5116;
19. Paris, M., Porcelloni, M., Binaschi, M., Fattori, D. (2008) Histone deacetylase inhibitors: from bench to clinic. Journal of Medicinal Chemistry, 51, 1505-1529;
20. Jones, P., Steinkuhler, C. (2008) From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents. Current Pharmaceutical Design, 14, 545-561.
21. Tsuji, N., Kobayashi, M., Nagashima, K., Wakisaka, Y. and Koizumi, K. (1976) A new antifungal antibiotic, trichostatin. Journal of Antibiotics (Tokyo), 29, 1-6.
22. Yoshida, M., Kijima, M., Akita, M. and Beppu, T. (1990) Potent and specific inhibition of mammalian HDAC both in vivo and in vitro by TSA. The Journal of Biological Chemistry, 265, 17174-17179.
23. Marks, P.A. and Breslow, R. (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nature Biotechnology, 25, 84-90.
24. Richon, V.M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L. et al. (1996) Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proceedings ofthe National Academy of Sciences ofthe United States ofAmerica, 93, 5705-5708.
25. Richon, V.M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R.A. et al. (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proceedings ofthe National Academy of Sciences of the United States of America, 95, 3003-3007.
26. Richon, V.M. (2006) Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. British Journal of Cancer, 95, S2-S6.
27. Duvic, M. and Zhang, C. (2006) Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. British Journal of Cancer, 95, S13-S19.
28. Olsen, E.A., Kim, Y.H., Kuzel, T.M., Pacheco, T.R., Foss, F.M., Parker, S. et al. (2007) Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology, 25, 3109-3115.
29. Kim, Y.B., Lee, K.-H., Sugita, K., Yoshida, M. and Horinouchi, S. (1999) Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene, 18, 2461-2470.
30. Jung, M., Hoffmann, K., Brosch, G. and Loidl, P. (1997) Analogues of trichostatin A and trapoxin B as histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 7, 1655-1658.
31. Jung, M., Brosch, G., Kolle, D., Scherf, H., Gerhauser, C. and Loidl, P. (1999) Amide analogues oftrichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. Journal of Medicinal Chemistry, 42, 4669-4679.
32. Remiszewski, S.W., Sambucetti, L.C., Atadja, P., Bair, K.W., Cornell, W.D., Green, M.A. et al. (2002) Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. Journal ofMedicinal Chemistry, 45, 753-757;
33. Woo, S.H., Frechette, S., Khalil, E.A., Bouchain, G., Vaisburg, A., Bernstein, N. et al. (2002) Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. Journal of Medicinal Chemistry, 45, 2877-2885.
34. Curtin, M.L., Garland, R.B., Heyman, H.R., Frey, R.R., Michaelides, M.R., Li, J. et al. (2002) Succinimide hydroxamic acids as potent inhibitors ofhistone deacetylase (HDAC). Bioorganic & Medicinal Chemistry Letters, 12, 2919-2923.
35. Dai, Y., Guo, Y., Guo, J., Pease, L.J., Li, J., Marcotte, P.A. et al. (2003) Indole amide hydroxamic acids as potent inhibitors of histone deacetylases. Bioorganic & Medicinal Chemistry Letters, 13,1897-1901.
36. Dai, Y., Guo, Y., Curtin, M.L., Li, J., Pease, L.J., Guo, J. et al. (2003) A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorganic & Medicinal Chemistry Letters, 13, 3817-3820.
37. Wu, T.Y.H., Hassig, C., Wu, Y., Ding, S. and Schultz, P.G. (2004) Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group. Bioorganic & Medicinal Chemistry Letters, 14, 449-453.
38. Remiszewski, S.W., Sambucetti, L.C., Bair, K.W., Bontempo, J., Cesarz, D., Chandramouli, N. et al. (2003) N-Hydroxy- 3-phenyl-2-propenamides as novel inhibitors of human HDAC with in vivo antitumor activity: discovery of NVP- LAQ824. Journal of Medicinal Chemistry, 46, 4609-4624.
39. Giles, F., Fischer, T., Cortes, J., Garcia-Manero, G., Beck, J., Ravandi, F. et al. (2006) A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clinical Cancer Research, 12, 4628-4635.
40. Revill, P., Mealy, N., Serradell, N., Bolos, J. and Rosa, E. (2007) Panobinostat. Drugs of the Future, 32, 315-322.
41. Lavoie, R., Bouchain, G., Frechette, S., Woo, S.H., Khalil, E.A., Leit, S. et al. (2001) Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 11, 2847-2850.
42. Finn, P.W., Bandara, M., Butcher, C., Finn, A., Hollinshead, R., Khan, N. et al. (2005) Novel sulfonamide derivatives as inhibitors ofhistone deacetylase. Helvetica Chimica Acta, 88, 1630-1657.
43. Plumb, J.A., Finn, P.W., Williams, R.J., Bandara, M.J., Romero, M.R., Watkins, C.J. et al. (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Molecular Cancer Therapeutics, 2, 721-728.
44. Buggy, J.J., Cao, Z.A., Bass, K.E., Verner, E., Balasubramanian, S., Liu, L. et al. (2006) CRA-024781: a novel synthetic inhibitor of HDAC enzymes with antitumor activity in vitro and in vivo. Molecular Cancer Therapeutics, 5, 1309-1317;
45. Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., Buggy, J.J. (2008) A novel histone deacetylase 8 (HDAC8)- specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia, 22, 1026-1034.
46. Golay, J., Cuppini, L., Leoni, F., Micò, C., Barbui, V., Domenghini, M. et al. (2007) The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia, 21, 1892-1900.
47. Arts, J., Angibaud, P., Mariën, A., Floren, W., Janssens, B., King, P. et al. (2007) R306465 is a novel potent inhibitor of class I HDACs with broad-spectrum antitumoral activity against solid and haematological malignancies. British Journal of Cancer, 97, 1344-1353.
48. Price, S., Bordogna, W., Braganza, R., Bull, R.J., Dyke, H.J., Gardan, S. et al. (2007) Identification and optimisation of a series of substituted 5-pyridin-2-yl- thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorganic & Medicinal Chemistry Letters, 17, 363-369;
49. Price, S., Bordogna, W., Bull, R.J., Clark, D.E., Crackett, P.H., Dyke, H.J. et al. (2007) Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2- hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorganic & Medicinal Chemistry Letters, 17, 370-375.
50. Witter, D.J., Belvedere, S., Chen, L., Secrist, J.P., Mosley, R.T. and Miller, T.A. (2007) Benzo[b]thio phene-based histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 17, 4562-4567.
51. Mai, A., Massa, S., Pezzi, R., Simeoni, S., Rotili, D., Nebbioso, A. et al. (2005) Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl) pyrrolyl hydroxyamides. Journal of Medicinal Chemistry, 48, 3344-3353.
52. Berger, M.R., Bischoff, H., Fritschi, E., Henne, T., Hermann, M., Pool, B.L. et al. (1985) Synthesis, toxicity, and therapeutic efficacy of 4-amino-N-(20-aminophenyl)- benzamide: a new compound preferentially active in slowly growing tumors. Cancer Treatment Reports, 69, 1415-1424.
53. Kraker, A.J., Mizzen, C.A., Hartl, B.G., Miin, J., Allis, C.D. and Merriman, R.L. (2003) Modulation of Histone Acetylation by [4-(Acetylamino)-N-(2-Amino-phenyl) Benzamide] in HCT-8 Colon Carcinoma. Molecular Cancer Therapeutics, 2, 401-408.
54. Hauschild, A. (2006) A phase II multicenter study on the HDACi MS-275, comparing two dosage schedules in metastatic melanoma. Abs. 8044, Annual Meeting of the American Society of Clinical Oncology, Atlanta, Ga.
55. Suzuki, T., Ando, T., Tsuchiya, K., Fukazawa, N., Saito, A., Mariko, Y. et al. (1999) Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. Journal of Medicinal Chemistry, 42, 3001-3003.
56. Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T. et al. (1999) A synthetic inhibitor of HDAC, MS-27-275, with marked in vivo antitumor activity against human tumors. Proceedings of the National Academy of Sciences of the United States of America, 96, 4592-4597.
57. Hess-Stump, H., Bracker, T.U., Henderson, D. and Politz, O. (2007) MS-275, a potent orally available inhibitor ofhistone deacetylases-The development of an anticancer agent. The International Journal of Biochemistry & Cell Biology, 39, 1388-1405.
58. Kell, J. and Serradell, N. (2008) MGCD- 0103. Drugs ofthe Future, 33, 323-327.
59. Fournel, M., Bonfils, C., Hou, Y, Yan, P.T., Trachy-Bourget, M.-C., Kalita, A. et al. (2008) MGCD0103, a novel isotype- selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Molecular Cancer Therapeutics, 7, 759-768.
60. Fournel, M., Trachy-Bourget, M.-C., Yan, P.T., Kalita, A., Bonfils, C., Beaulieu, C. et al. (2002) Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Research, 62, 4325-4330.
61. Bouchain, G., Leit, S., Frechette, S., Khalil, E.A., Lavoie, R., Moradei, O. et al. (2003) Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors. Journal of Medicinal Chemistry, 46, 820-830.
62. Moradei, O., Leit, S., Zhou, N., Frechétte, S., Paquin, I., Raeppel, S. et al. (2006) Substituted N-(2-aminophenyl)- benzamides, (E)-N-(2-aminophenyl)- acrylamides and their analogues: Novel classes of histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 16, 4048-4052.
63. Vaisburg, A., Paquin, I., Bernstein, N., Frechette, S., Gaudette, F., Leit, S. et al. (2007) N-(2-Amino-phenyl)-4- (heteroarylmethyl)-benzamides as new histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 17, 6729-6733.
64. Fréchette, S., Leit, S., Woo, S.H., Lapointe, G., Jeannotte, G., Moradei, O. et al. (2008) 4-(Heteroarylaminomethyl)-N- (2-aminophenyl)-benzamides and their analogs as a novel class ofhistone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 18,1502-1506.
65. Hamblett, C.L., Methot, J.L., Mampreian, D.M., Sloman, D.L., Stanton, M.G., Kral, A.M. et al. (2007) The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 17, 5300-5309.
66. Andrews, D.M., Gibson, K.M., Graham, M.A., Matusiak, Z.S., Roberts, C.A., Stokes, E.S.E. et al. (2008) Design and campaign synthesis of pyridine-based histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 18, 2525-2529.
67. Andrews, D.M., Stokes, E.S.E., Carr, G.R., Matusiak, Z.S., Roberts, C.A.,Waring, M.J. et al. (2008) Design and campaign synthesis ofpiperidine- and thiazole-based histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 18, 2580-2584.
68. Moradei, O.M., Mallais, T.C., Frechette, S., Paquin, I., Tessier, P.E., Leit, S.M. et al. (2007) Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. Journal of Medicinal Chemistry, 50, 5543-5546;
69. Witter, D.J., Harrington, P., Wilson, K.J., Chenard, M., Fleming, J.C., Haines, B. et al. (2008) Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2). Bioorganic & Medicinal Chemistry Letters, 18, 726-731;
70. Methot, J.L., Chakravarty, P.K., Chenard, M., Close, J., Cruz, J.C., Dahlberg, W.K. et al. (2008) Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorganic & Medicinal Chemistry Letters, 18, 973-978.
71. Haggarty, S.J., Koeller, K.M., Wong, J.C., Grozinger, C.M. and Schreiber, S.L. (2003) Domain-selective small-molecule inhibitor of HDAC6-mediated tubulin deacetylation. Proceedings ofthe National Academy ofSciences ofthe United States of America, 100, 4389-4394.
72. Frey, R.R., Wada, C.K., Garland, R.B., Curtin, M.L., Michaelides, M.R., Li, J. et al. (2002) Trifluoromethyl ketones as inhibitors of HDAC. Bioorganic & Medicinal Chemistry Letters, 12, 3443-3447.
73. Vasudevan, A., Ji, Z., Frey, R.R., Wada, C.K., Steinman, D., Heyman, H.R. et al. (2003) Heterocyclic ketones as inhibitors of HDAC. Bioorganic & Medicinal Chemistry Letters, 13, 3909-3913.
74. Wada, C.K., Frey, R.R., Ji, Z., Curtin, M.L., Garland, R.B., Holms, J.H. et al. (2003) α-Keto amides as inhibitors of HDAC. Bioorganic & Medicinal Chemistry Letters, 13, 3331-3335.
75. Lahm, A., Paolini, C., Pallaoro, M., Nardi, M.C., Jones, P., Neddermann, P. et al. (2007) Unraveling the hidden catalytic activity of vertebrate class IIA histone deacetylases. Proceedings ofthe National Academy ofSciences ofthe United States of America, 104, 17335-17340;
76. Jones, P., Altamura, S., De Francesco, R., Gallinari, P., Lahm, A., Neddermann, P. et al. (2008) Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorganic & Medicinal Chemistry Letters, 18, 1814-1819.
77. Ueda, M., Manda, T., Matsumoto, S., Mukumoto, S., Nishigaki, F., Kawamura, I. et al. (1994) FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. Journal ofAntibiotics (Tokyo), 47, 315-323.
78. Nakajima, H., Kim, Y.B., Terano, H., Yoshida, M. and Horinouchi, S. (1998) FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Experimental Cell Research, 241, 126-133.
79. Furumai, R., Matsuyama, A., Kobashi, N., Lee, K.-H., Nishiyama, M., Nakajima, H. et al. (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I HDACs. Cancer Research, 62, 4916-4921.
80. Whittaker, S., Scarisbrick, J., Kim, Y.H., Reddy, S., Kim, E.J., Rook, A.H. et al. (2008) Romidepsin activity and clinical benefit in refractory CTCL: results from an international multicenter study. Abstract 444, 5th Joint Meeting of the JSID, SID and ESDR, Kyoto.
81. Walton, J.D. (2006) HC-toxin. Phytochemistry, 67, 1406-1413.
82. Brosch, G., Ransom, R., Lechner, T., Walton, J.D. and Loidl, P. (1995) Inhibition ofmaize histone deacetylases by HC toxin, the host-selective toxin of Cochliobolus carbonum. Plant Cell, 7, 1941.
83. Closse, A. and Huguenin, R. (1974) Isolierung und strukturaufklärung von chlamydocin. Helvetica Chimica Acta, 57, 533-545.
84. De Schepper, S., Bruwiere, H., Verhulst, T., Steller, U., Andries, L., Wouters, W. et al. (2003) Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin. The Journal ofPharmacology and Experimental Therapeutics, 304, 881-888.
85. Itazaki, H., Nagashima, K., Sugita, K., Yoshida, H., Kawamura, Y., Yasuda, Y. et al. (1990) Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. Journal of Antibiotics (Tokyo), 43, 1524-1532.
86. Kijima, M., Yoshida, M., Sugita, K., Horinouchi, S. and Beppu, T. (1993) Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. The Journal of Biological Chemistry, 268, 22429-22435.
87. Taunton, J., Collins, J.L. and Schreiber, S.L. (1996) Synthesis of natural and modified trapoxins, useful reagents for exploring histone deacetylase function. Journal ofthe American Chemical Society, 118, 10412-10422.
88. Mori, H., Urano, Y, Abe, F., Furukawa, S., Furukawa, S., Tsurumi, Y. et al. (2003) FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC). I. Taxonomy, fermentation, isolation and biological activities. Journal of Antibiotics (Tokyo), 56, 72-79.
89. Mori, H., Yoshimura, S., Takase, S. and Hino, M. (2000) Inhibitor of histone deacetylase, WO2000/08048.
90. Darkin-Rattray, S.J., Gurnett, A.M., Myers, R.W., Dulski, P.M., Crumley, T.M., Allocco, J.J. et al. (1996) Apicidin: A novel antiprotozoal agent that inhibits parasite HDAC. Proceedings of the National Academy of Sciences of the United States of America, 93, 13143-13147.
91. WAF1/Cip1 and gelsolin. Cancer Research, 60, 6068-6074.
92. Nakao, Y., Yoshida, S., Matsunaga, S., Shindoh, N., Terada, Y, Nagai, K. et al. (2006) Azumamides A-E: histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge. Mycale izuensis Angewandte Chemie (International Edition in English), 45, 7553-7557.
93. Pina, I.C., Gautschi, J.T., Wang, G.-Y.-S., Sanders, M.L., Schmitz, F.J., France, D. et al. (2003) Psammaplins fromthe sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. The Journal ofOrganic Chemistry, 68, 3866-3873.
94. Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M. and Horinouchi, S. (2001) Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proceedings of the National Academy of Sciences of the United States of America, 98, 87-92.
95. Komatsu, Y., Tomizaki, K., Tsukamoto, M., Kato, T., Nishino, N., Sato, S. et al. (2001) Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Research, 61, 4459-4466.
96. Nishino, N., Jose, B., Okamura, S., Ebisusaki, S., Kato, T., Sumida, Y. et al. (2003) Cyclic tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases. OrganicLetters, 5, 5079-5082.
97. Jones, P., Altamura, S., Chakravarty, P.K., Cecchetti, O., De Francesco, R., Gallinari, P. et al. (2006) A series of novel, potent, and selective histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 16, 5948-5952.
98. Jones, P., Altamura, S., De Francesco, R., Gonzalez Paz, O., Kinzel, O., Mesiti, G. et al. (2008) A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. Journal ofMedicinal Chemistry, 51, 2350-2353.
99. Suzuki, T., Nagano, Y., Kouketsu, A., Matsuura, A., Maruyama, S., Kurotaki, M. et al. (2005) Novel Inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. Journal ofMedicinal Chemistry, 48, 1019-1032.
100. Suzuki, T., Kouketsu, A., Itoh, Y., Hisakawa, S., Maeda, S., Yoshida, M. et al. (2006) Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. Journal of Medicinal Chemistry, 49, 4809-4812;
101. Itoh, Y., Suzuki, T., Kouketsu, A., Suzuki, N., Maeda, S., Yoshida, M. et al. (2007) Design, synthesis, structure- selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. Journal of Medicinal Chemistry, 50, 5425-5438.
102. Chen, B., Petukhov, P.A., Jung, M., Velena, A., Eliseeva, E., Dritschilo, A. and Kozikowski, A.P. (2005) Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 15, 1389-1392.
103. Kozikowski, A.P., Chen, Y., Gaysin, A., Chen, B., D'Annibale, M.A., Suto, C.M. et al. (2007) Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. Journal of Medicinal Chemistry, 50, 3054-3061.
104. Hassig, C.A., Symons, K.T., Guo, X., Nguyen, P.-M., Annable, T., Wash, P.L. et al. (2008) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo Mol. Cancer Therapeutics, 7, 1054-1065.